p53 upregulated modulator of apoptosis

Zentalis Pharmaceuticals Announces FDA Clearance of IND Application for ZN-d5 for the Treatment of Hematologic Malignancies

Retrieved on: 
Thursday, April 30, 2020
Branches of biology, Cell biology, Biology, Programmed cell death, Bcl-2, Oncogenes, Apoptosis, Selective estrogen receptor degrader, Cancer, p53 upregulated modulator of apoptosis, Germinal center B-cell like diffuse large B-cell lymphoma

BCL-2 is as an important mediator in restoring the normal apoptotic process in tumor cells, making this protein a vital target for the treatment of cancer.

Key Points: 
  • BCL-2 is as an important mediator in restoring the normal apoptotic process in tumor cells, making this protein a vital target for the treatment of cancer.
  • ZN-d5, a BCL-2 inhibitor, may offer patients with hematologic and epithelial malignancies a differentiated therapy option, both as a monotherapy and in combination with other agents including our oral selective estrogen receptor degrader (SERD), ZN-c5.
  • We believe a BCL-2 inhibitor will restore the normal apoptosis process, making it an important target for cancer treatments.
  • Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.